AbbVie (ABBV) : The total money flow in AbbVie (ABBV) was negative ($48.74 million), showing the domination of sellers in the Tuesday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $153.04 million. Transactions on upticks were comparatively lower at $104.31 million. The uptick to downtick ratio was 0.68. The total block trades done on upticks were valued at $5.84 million. The total block trades on downticks were valued at $61.23 million. The uptick to the downtick ratio of block trades was 0.1. The money flow during block trades was negative ($55.38 million) when the stock traded with a gain of $115 cent. AbbVie (ABBV) was $65.5, an increase of 1.79% over the previous days close.
The company Insiders own 0.11% of AbbVie shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.87% . Institutional Investors own 66.75% of AbbVie shares. During last six month period, the net percent change held by insiders has seen a change of -14.58%. In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Officer (Executive Vice President) of AbbVie Inc., Schumacher Laura J had sold 186,106 shares worth of $11,179,387 in a transaction dated June 24, 2016. In this transaction, 186,106 shares were sold at $60.07 per share.
Shares of AbbVie Inc. rose by 5.78% in the last five trading days and 7.38% for the last 4 weeks. AbbVie Inc. is up 10.42% in the last 3-month period. Year-to-Date the stock performance stands at 12.8%.
AbbVie (NYSE:ABBV): stock turned positive on Tuesday. Though the stock opened at $64.67, the bulls momentum made the stock top out at $65.81 level for the day. The stock recorded a low of $64.32 and closed the trading day at $65.5, in the green by 1.79%. The total traded volume for the day was 11,870,533. The stock had closed at $64.35 in the previous days trading.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.